Growth Hormone · Approved medicine
Tesamorelin
Stabilised GHRH analogue · Growth · Metabolic · Weight
An FDA-approved GHRH analogue with real Phase 3 evidence behind its indication.
- Form
- 10 mg — pre-reconstituted in the Cellvéra injector
- Oversight
- Licensed clinician, included
- Price
- From R5 225 / protocol
Opens a private email to our concierge · nothing is charged
Checkout begins your confidential medical intake. Tesamorelin is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.
Pathway
A stabilised analogue of growth-hormone-releasing hormone, sold as the medicine Egrifta and FDA-approved since 2010. A chemical group added to the front of the molecule protects it from rapid breakdown.
Mechanism
Acts on the pituitary to increase natural growth-hormone release, with a particular effect on visceral fat — the deep abdominal fat packed around the organs, as distinct from fat under the skin.
Studied for
- Reduction of visceral abdominal fat (its approved use, in HIV-associated lipodystrophy)
- Fatty liver disease in people with HIV
- Cognition in mild cognitive impairment — studied, not approved
Areas of research interest — not promised outcomes.
Where the evidence stands
Real Phase 3 evidence supporting roughly a 15–18% reduction in visceral fat in its approved population. A properly evidenced drug — but the evidence is for a specific patient group, not for general body recomposition.
Typical protocol
1–2 mg subcutaneous daily, exactly as prescribed and monitored by your supervising clinician.
Contraindications & cautions
Pregnancy. Active malignancy. Raises IGF-1 and can worsen glucose tolerance. Commonly causes injection-site reactions and joint pain.
Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.